2020
DOI: 10.1097/hs9.0000000000000479
|View full text |Cite
|
Sign up to set email alerts
|

Gene Therapy of the Hemoglobinopathies

Abstract: Sickle cell disease and the ß-thalassemias are caused by mutations of the ß-globin gene and represent the most frequent single gene disorders worldwide. Even in European countries with a previous low frequency of these conditions the prevalence has substantially increased following large scale migration from Africa and the Middle East to Europe. The hemoglobin diseases severely limit both, life expectancy and quality of life and require either life-long supportive therapy if cure cannot be achieved by allogene… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
21
0
7

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 26 publications
(28 citation statements)
references
References 150 publications
(445 reference statements)
0
21
0
7
Order By: Relevance
“…The transduced stem cells are then reinfused into the patient where the modified cells replicate, repopulate the blood compartment, and facilitate normal hemoglobin synthesis (Figure 2). [73,74] The first gene therapy, betibeglogene autotemcel (beti-cel; bluebird bio), is currently in clinical trials in the USA for patients with TD β-thalassemia aged ≤ 50 years for whom HSCT is appropriate but no HLA-matched donor is available. Beti-cel is a genetically modified autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with a lentiviral vector encoding the β A-T87Q -globin gene [75].…”
Section: Beti-cel Gene Therapymentioning
confidence: 99%
“…The transduced stem cells are then reinfused into the patient where the modified cells replicate, repopulate the blood compartment, and facilitate normal hemoglobin synthesis (Figure 2). [73,74] The first gene therapy, betibeglogene autotemcel (beti-cel; bluebird bio), is currently in clinical trials in the USA for patients with TD β-thalassemia aged ≤ 50 years for whom HSCT is appropriate but no HLA-matched donor is available. Beti-cel is a genetically modified autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with a lentiviral vector encoding the β A-T87Q -globin gene [75].…”
Section: Beti-cel Gene Therapymentioning
confidence: 99%
“…Retroviral vectors have been used for over 20 years for in vivo and ex vivo gene therapies with significant advantages such as the long-term and stable transgene expression into the host genome, owing to their ability to infect only dividing cells (hematopoietic stem cells). On the other hand, the permanent integration of the vector genome into the host genome can pose additional risks and, in particular, there is a possibility of triggering cellular oncogenesis, as the transgenic material is randomly integrated, which can lead to the development of malignancies [ 115 , 127 , 128 ]. Later, the development of self-inactivating retroviral vectors was a major step forward to reduce the aforementioned risks, at least in theory; however, the integration mechanisms of retroviruses remain quite where they usually lead to sub-therapeutic levels, in terms of efficiency.…”
Section: Viral Vectorsmentioning
confidence: 99%
“…Based on the latest report for active gene therapy clinical trials, 35 out of 50 transfusion-dependent thalassemia patients, between ages 5 and 64 years old, were successfully treated, and in most patients, the transfusion was reduced or discontinued. The majority of the patients did not show any severe adverse events in relation to vector integration and gene therapy conditions [ 128 , 164 ]. In 2018, among the aforementioned patients, a new protocol was designed where the transduction has been made in CD34 + cells, using a new vector called GLOBE, and then administered by intraosseous infusion to the posterior-superior iliac crests.…”
Section: Clinical Applications In Patients With β-Type Hemoglobinopathiesmentioning
confidence: 99%
“…No drug-related AEs were reported beyond 2 years post-infusion. Longer-term safety data for this novel, and potentially curative, therapy option are needed, particularly given concerns regarding the possible risk of oncogene activation due to insertional mutagenesis [49]. Recently, the serious AE of acute myeloid leukemia (AML) reported in a related clinical trial of gene therapy in patients with sickle cell disease was determined to be very unlikely related to the lentiviral vector used; as such, the U.S. Food and Drug Administration (FDA) has lifted the hold on the ongoing clinical trials in patients with sickle cell and β-thalassemia [50].…”
Section: Gene Therapymentioning
confidence: 99%